Key Highlights

  • Karyopharm Therapeutics (NASDAQ:KPTI) filed voluntary Chapter 11 petitions in the Southern District of Texas, according to a company filing dated November 2, 2026, alongside a restructuring support agreement with lenders and noteholders.
  • The company is seeking a USD 110 million superpriority debtor-in-possession term loan, of which up to USD 55 million is new money and the remainder rolls up existing loans, maturing no later than May 1, 2027.
  • The filing says common stock and convertible preferred stock would receive no distribution under the prepackaged plan, and the company expects its existing Equity securities will have no value.
  • Published market data showed KPTI near USD 0.10, up 9.17%, on Volume of about 24.457 million shares; the snapshot date could not be confirmed, so these figures are treated as unverified.

Chapter 11 Filing Pairs With a Merger Proposal

Karyopharm Therapeutics (NASDAQ:KPTI), a commercial-stage drugmaker based in Newton, Massachusetts, disclosed in a Form 8-K dated November 2, 2026 that it signed a restructuring support agreement and filed Chapter 11 cases. The agreement contemplates a merger between private company Ayrmid Ltd. and a reorganized Karyopharm, to be completed through a court-approved plan. The company will ask the court to approve bidding procedures that allow competing bids for its assets. The transaction is expected to close in the first quarter of 2027, subject to plan conditions.

Debt Terms, Going Concern Doubt and the Road to the Filing

The path to the filing was visible in earlier disclosures. In its Quarterly Report for the period ended March 31, 2026, the company reported cash of USD 90.9 million, a term Loan principal of USD 124.6 million, a stockholders' Deficit of USD 265.6 million, and substantial doubt about its ability to continue as a going concern. First-quarter Revenue was USD 35.1 million against a net loss of USD 22.4 million. A forbearance agreement dated September 10, 2026 was extended to October 22 and then to November 1, 2026, and the Chapter 11 filing ended that period. New-money debtor-in-possession loans carry interest at SOFR, with a 3% floor, plus 9.00%, while roll-up loans carry SOFR plus 12.25%.

Penny Stock Risks When Equity May Be Cancelled

At about USD 0.10, KPTI screens as a penny stock, but the price reflects a Bankruptcy process rather than a typical small-cap setback. The filing warns that trading in the company's securities during the cases is highly speculative and that prices may bear little relation to any eventual recovery. In a penny stock, a small number of trades can move the price, spreads can be wide, and a quoted gain can reverse quickly, so a 9.17% move does not suggest a trend. Comparison of the 24.457 million share volume with normal levels was not available. No exchange delisting notice was found in the material reviewed, and the company has not said how its Nasdaq listing will be treated.

Where Things Stand

Karyopharm trades near USD 0.10 because its own filing says existing shareholders should expect no value from the prepackaged plan, which hands the Business to lenders and a merger partner. The 9.17% gain in published market data does not change that disclosure. What matters next is the bankruptcy court calendar: approval of the debtor-in-possession loan, bidding procedures that could invite rival offers, and the expected first-quarter 2027 close of the Ayrmid merger. A competing bid would be the main change to watch.